Merck MRK, known as MSD outside the United States and Canada,
and AstraZeneca AZN today announced a worldwide licensing
agreement for Merck's oral small molecule inhibitor of WEE1 kinase
(MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical
studies in combination with standard-of-care therapies for the treatment
of patients with certain types of ovarian cancer.
WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor
MK-1775 is designed to cause certain tumor cells to divide without
undergoing normal DNA repair processes, ultimately leading to cell
death. Preclinical evidence suggests that the combination of MK-1775 and
DNA damage-inducing chemotherapy agents can enhance anti-tumor
properties, in comparison to chemotherapy alone.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in